Sygnature Discovery to partner with UCL School of Pharmacy for £1m pancreatic cancer research project

Sygnature Discovery, the UK’s largest independent drug discovery expert and research partner, has been appointed by UCL to lead an optimisation project targeting pancreatic cancer. The project is based upon research done by Professor Stephen Neidle’s group in the UCL School of Pharmacy, in collaboration with the UCL Drug Discovery Group, led by Dr Richard […]

Read more

UCL Technology Fund Annual Investment Review

The UCL Technology Fund commenced operation in January 2016, and we are pleased to now share a summary of the breadth and depth of projects we’ve funded in both life and physical sciences projects across UCL. UCLTF Brochure – Summer 2017

Read more

UCL Technology Fund has approved investment of up to £1m in the development of a gene therapy for p47-CGD

The UCL Technology Fund (UCLTF), has approved an investment of up to £1m to support Professor Adrian Thrasher, Professor Bobby Gaspar, and Dr Giorgia Santilli’s development of a gene therapy for p47phox-deficient chronic granulomatous disease (p47-CGD) through to a clinical trial in which it could potentially cure patients completely of this devastating disease. p47-CGD is a […]

Read more

Professor John Greenwood speaks at the UCLTF lunchtime seminar in the Quad

Can you be a basic scientist and still translate your research? Being a scientist interested in fundamental mechanisms and being able to identify therapeutic and commercial opportunity are not mutually exclusive activities. It’s about learning to recognise commercial opportunity in your research, scientifically prove its potential and understand the pathway to development. This often takes […]

Read more

UCLTF fund drug development platform Canbex for the treatment of multiple sclerosis

Canbex was established to develop the VSN compound series, a drug development platform with potential applications in a wide range of therapeutic areas due to its mechanism of action. The lead molecule of the series, VSN16R, is in a Phase II trial for the treatment of spasticity in people with multiple sclerosis.  

Read more

Orchard Therapeutics Ltd. Announces a Manufacturing Alliance with PharmaCell B.V.

Orchard announces an alliance with PharmaCell B.V. (“PharmaCell”), a leading Contract Manufacturing Organization (CMO) for Cell and Gene Therapies and Regenerative Medicine. Under the terms of the alliance, PharmaCell will provide GMP-compliant manufacturing services to support clinical trials and commercialization of Orchard’s ex-vivo autologous gene therapy products. This agreement represents another important milestone for Orchard’s strategy […]

Read more

UCL Technology Fund invests £1m in to School of Pharmacy project to treat pancreatic cancer

  The UCL Technology Fund (UCLTF), which provides funding and support for UCL’s most transformative innovations, has approved an investment of up to £1m in Professor Stephen Neidle’s ‘G-Quadruplex’ Targeting project, which has the potential to treat pancreatic and other cancers. Pancreatic cancer is devastating and almost always refractory to treatment, resulting in rapid and […]

Read more

Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedica

Orchard Therapeutics has announced that it has entered into a strategic alliance with Oxford BioMedica plc., a world-leading company in gene and cell therapy. Under the terms of the collaboration and licence agreement, Oxford BioMedica has granted an exclusive intellectual property licence to Orchard for collaboration programmes, and will provide process development services and manufacture […]

Read more